Salute e Benessere

Product Quality Elevated with Environmental Test Chambers: Global Market to Hit…

In 2023, the environmental test chambers market will be worth US$ 915.3 million. The demand for environmental test chambers is projected to expand at an average CAGR of 4.6% between 2023 and 2033. Environmental test chamber makers are expected to earn up to US$ 1,435.1 million in sales by 2033. In 2023, the environmental test chambers market will be worth US$ 915.3 million . The demand for environmental test chambers is projected to expand at an averageCAGR of 4.6%between 2023 and 2033...
PR Newswire
15/11/2023

1 in 25 carries a genotype that is associated with a shortened lifespan

Utilizing a list of 73 actionable genes from the guidelines from the American College of Medical Genetics and Genomics (ACMG), the scientists found that 4% of Icelanders carry an actionable genotype in one or more of these genes. The diseases caused by these genotypes include cardiovascular, cancer, and metabolic diseases. The study assessed the relationship between actionable genotypes and the lifespan of their carriers. The largest effect was observed among carriers of...
PR Newswire
15/11/2023

Tumor Ablation Market to Reach $5.0 Billion, by 2032 at 13.5% CAGR: Allied…

Request Sample of the Report on Tumor Ablation Market Forecast 2032- https://www.alliedmarketresearch.com/request-sample/17626 Request Sample of the Report on Tumor Ablation Market Forecast 2032-https://www.alliedmarketresearch.com/request-sample/17626 Prime determinants of growth The tumor ablation market has experienced significant growth due to increase in the prevalence of cancers across the globe and the increase in demand for minimally invasive tumor ablation techniques...
PR Newswire
15/11/2023

International Group of Scientists Offers Proven Solution to Global Conflict

Cost? Less than One Day of War Cost? Less than One Day of War Dr. Tony Nader, Chairman of the Global Union of Scientists for Peace, said this innovative solution would "cost less than one day of war." "The solution is based in the most fundamental value of life: consciousness," Dr. Nader said. Scientifically Confirmed by 56 Studies Dr. Nader said, "Research has found that small groups practicing the Transcendental Meditation and advanced TM-Sidhi program together create…
PR Newswire
15/11/2023

Alma, a Sisram Medical company, reinforces its APAC leadership with the…

Japan's medical aesthetic market, ranked as the third largest, is rapidly and consistently growing. While Alma has been operating in the Japanese market since the year 2000, establishing sales channels, as well as strong relationships with clinics and esteemed professionals across the country, the opening of the Japan direct office marks a new level of commitment to the Japanese market, to better serve Japanese doctors, understand patients' desires and needs, and tailor-made innovative solutions…
PR Newswire
15/11/2023

Ethicon Introduces ETHIZIA™ Hemostatic Sealing Patch, Clinically Proven to Stop…

ETHIZIA™ Hemostatic Sealing Patch has received CE Mark approval as an adjunctive hemostat for disruptive bleeding on internal organs, except cardiovascular and neurological, and is expected to launch in EMEA in Q1 2024, and other key markets in North America, APAC and LATAM following regulatory approvals. ETHIZIA™ Hemostatic Sealing Patch has received CE Mark approval as an adjunctive hemostat for disruptive bleeding on internal organs, except cardiovascular and neurological, and is expected...
PR Newswire
15/11/2023

Evaxion Presents Proof-of-Principle for Its Unique AI Model Predicting Responses…

Evaxion today presents a novel AI model designed to predict patient responses to standard-of-care cancer immunotherapyThe model demonstrates promising potential for improving patient outcomes, reducing healthcare costs and is scalable for broader applicationsEvaxion will pursue a partnership-based approach towards a commercial offering COPENHAGEN, Denmark, Nov.15, 2023(GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio...
Nasdaq GlobeNewswire
15/11/2023

New Published Study Demonstrates Safety and Feasibility of Filterlex Medical's…

TAVR is an emerging minimal invasive alternative treatment to surgery in patients with aortic stenosis. The increased risk in peri-procedural stroke is the result of calcified heart valve or tissue particles that break loose and travel in the bloodstream towards the brain. In the published study, the CAPTIS® system captured a high number of embolic debris particles, providing embolic protection and enhancing safety during TAVR procedures. TAVR is an emerging minimal invasive alternative...
PR Newswire
15/11/2023

AIM ImmunoTech Reports Third Quarter 2023 Financial Results and Provides…

– Highlights continued execution across Ampligen ®clinical development programs – Company is well positioned to achieve multiple value-driving milestones during remainder of 2023 and 2024– Will host conference call and webcast today, November 15 that 8:30 AM ET OCALA, Fla., Nov.15, 2023(GLOBE NEWSWIRE) -- AIM ImmunoTech Inc.(NYSE American: AIM) (“AIM” or the “Company”) today reported financial results for the third quarter 2023 and provided a business update...
Nasdaq GlobeNewswire
15/11/2023

The PolG Foundation awards over $3.5M in academic grants to pioneer POLG…

With both a dedicated and experienced Board of Directors and Scientific Advisory Board, including some of the top mitochondrial scientists in the world, the Foundation is quickly becoming a leading funder of basic, translational, and clinical PolG research. Working with the global scientific community, we are investing in developing critical tools and continue to make our findings available to mitochondrial scientists, clinicians, and patients worldwide. With both a dedicated and experienced...
PR Newswire
15/11/2023

Alkermes Completes Separation of Oncology Business

DUBLIN, Nov. 15, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it has completed the separation of its oncology business into Mural Oncology plc (Mural Oncology), a new, independent, publicly traded company. Alkermes is now a pure-play, profitable neuroscience company that will continue its work to develop innovative medicines for people living with difficult-to-treat psychiatric and neurological disorders. Mural Oncology will begin "regular way" trading on the…
PR Newswire
15/11/2023

Juliusz Rakowski starts as CEO of BBS: "My focus is already on the time after…

BBS-Bioactive Bone Substitutes Oyj, Investor News, 15 November 2023 at 12.50 p.m. Last week, Juliusz Rakowski officially started as CEO of BBS-Bioactive Bone Substitutes Oyj (BBS). The first week included getting to know the personnel and owners as well as the company's offices and production facilities in Oulu and Reisijärvi. In the very beginning, Juliusz's focus will be strictly on finalizing the CE marking process of the company's first product, currently in its final stages, but...
Nasdaq GlobeNewswire
15/11/2023

Feminine Hygiene Products Market worth $32.2 billion by 2028 - Exclusive Report…

264 – Tables 264 – Tables 45 – Figures 230 – Pages Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=69114569 The disposable segment accounted for the largest feminine hygiene products market share in 2022. By nature, the disposable category dominated the market share in 2022. This category encompasses feminine hygiene products like sanitary pads, tampons, and panty liners. Over the past few decades, disposable absorbent feminine hygiene...
PR Newswire
15/11/2023

Compass Pathways initiates UK component of global phase 3 study of psilocybin…

UK sites to participate in part of pivotal phase 3 program following Medicines and Healthcare Regulatory Agency approval of studyResearch will take place in the UK, including at the newly opened Centre for Mental Health Research and Innovation in London, developed in partnership with South London and Maudsley NHS Foundation Trust and the Institute of Psychiatry, Psychology & Neuroscience at King's College LondonLONDON, Nov.15, 2023(GLOBE NEWSWIRE) -- Compass Pathways plc...
Nasdaq GlobeNewswire
15/11/2023

BMC Celebrates World COPD Day 2023 With Innovative Products and Global Events

Early diagnosis and treatment of COPD can slow down the progression of the disease, reduce the risk of complications, and improve the symptoms and quality of life of the patients. There are various treatment options available for COPD, such as medication, oxygen therapy, pulmonary rehabilitation, surgery, and non-invasive ventilation. The choice of treatment depends on the severity of the disease, the patient's preferences, and the availability of resources.3 Early diagnosis and treatment of...
PR Newswire
15/11/2023

Gilde Healthcare closes new Venture&Growth fund at €740 million hard cap

Pieter van der Meer, Managing Partner at Gilde Healthcare: "Thestrong interest from institutional investors driven to make a substantial impact, is a clear endorsement of our mission: investing in solutions to improve the quality of patient care while keeping it affordable. Our broad strategy, covering digital health, MedTech and therapeutics, results in a holistic approach allowing us to select the most optimal and cost effective solution for the individual patient. With a team of sector…
PR Newswire
15/11/2023

The Shaw Prize Award Presentation Ceremony 2023: Celebrating 20 Years of…

The highlight of the night was the presentation of awards to Shaw Laureates 2023, including Professors Matthew Bailes, Duncan Lorimer, and Maura McLaughlin in Astronomy; Professors Patrick Cramer and Eva Nogales in Life Science and Medicine; and Professors Vladimir Drinfeld and Shing-Tung Yau in Mathematical Sciences, by Professor Reinhard Genzel, Chair of the Board of Adjudicators. Laureates from 2020-2022, who had previously received their certificates remotely due to the pandemic, were also…
PR Newswire
15/11/2023

Cellectis Announces the execution of the Subsequent Investment Agreement with…

Execution of binding subsequent investment agreement regarding contemplated additional equity investment of $140M by AstraZeneca, previously announced on November 1, 2023. Extraordinary shareholders' meeting of Cellectis to be held on or around December 22, 2023 to approve such investment.NEW YORK, Nov.15, 2023(GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) today anounced that, following the consultation of its works council, it has now signed a binding...
Nasdaq GlobeNewswire
15/11/2023

Implantica's RefluxStop™ makes an impact at the leading Annual European Foregut…

The RefluxStop™ symposium was moderated by Univ.-Prof. Dr. Sebastian F. Schoppmann, Associate Professor of Surgery, Medizinische Universität Wien, University Hospital in Vienna, Austria. He was joined by seven other leading GERD surgeons and GI experts from Germany, UK, Switzerland, US and Italy, highlighting their clinical perspectives and experiences with RefluxStop™ therapy from several hundreds of patients. The RefluxStop™ symposium was moderated by Univ.-Prof. Dr.Sebastian F. Schoppmann...
PR Newswire
15/11/2023

Kanazawa University research: Researchers fix the chirality of helical proteins

Helical proteins are chiral molecules, which means that the molecule's shape cannot be fitted into its mirror image. In nature helical proteins often have other chiral components, such as sugars or amino acids, and these will determine which way the protein coils. However, there is a lot of interest in synthesizing artificial helical proteins that have different chemical components and hence functions not found in nature, and these may not have other chiral components. Nonetheless having both…
PR Newswire
15/11/2023

Orion Research Foundation grants EUR 1,112,000 for research in 2024

Orion Research Foundation grants EUR 1,112,000 for research in 2024Press release 15 November, 2023 at 9.00 EET Orion Research Foundation sr is distributing EUR 1,112,000 in research grants based on applications for 2024. Orion Reaserch Foundation awards grants of max EUR 50,000 for 17 researchers for postdoctoral research and max EUR 6,000 for 95 young researchers for doctoral dissertation work. One of the postdoctoral grants was distributed from Maritza and Reino Salonen's Fund which is...
Nasdaq GlobeNewswire
15/11/2023

T-Therapeutics raises £48 million Series A for development of next generation…

T-Therapeutics raises £48 million Series A for development of next generation TCR therapeutics to transform cancer treatmentFundraise led by Sofinnova Partners, F-Prime Capital, Digitalis Ventures and Cambridge Innovation Capital with participation from Sanofi Ventures and the University of Cambridge Venture FundUnique transgenic mouse platform harnesses natural power of T cells to build a portfolio of first-in-class cancer medicines 15 November 2023; Cambridge, England–...
Nasdaq GlobeNewswire
15/11/2023

Valneva Announces the Availability of Documentation for its Extraordinary…

Saint-Herblain (France), November 15, 2023–Valneva SE(Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the availability of documentation for its Extraordinary General Meeting (“General Meeting” or “EGM”) which will be held on December 20, 2023 at 2:00 p.m. CET at the Radisson Blu Hotel, 6 place Aristide Briand, 44000 Nantes, France.As announced in June 2023 1, during this EGM, shareholders will notably vote on the Supervisory Board's recommendation to...
Nasdaq GlobeNewswire
15/11/2023

NMD Pharma Raises €75 Million (~$80 million) in a Series B Financing

Proceeds will be used to complete three Phase 2 clinical studies of first-in-class ClC-1 molecule inhibitor NMD670 in myasthenia gravis, spinal muscular atrophy and Charcot-Marie-Tooth disease In addition, NMD Pharma will continue to mature and expand its pipeline of novel ClC-1 inhibitors, and pursue undisclosed targets for other neuromuscular diseases Aarhus, Denmark, 15 November 2023 –NMD Pharma A/S, a clinical-stage biotech dedicated to developing novel and improved...
Nasdaq GlobeNewswire
15/11/2023
Altri  Comunicati